Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada | Zendy

Simon R. Knowles | Zendy; Elizabeth J. Phillips | Zendy; Linda Dresser | Zendy; Larissa Matukas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada

Author(s) -

Simon R. Knowles,

Elizabeth J. Phillips,

Linda Dresser,

Larissa Matukas

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/378304

Subject(s) - ribavirin , medicine , adverse effect , respiratory system , intensive care medicine , virology , virus , hepatitis c virus

Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research